Poor
Mostly Not Aligned
Patient Risk:
Moderate
Summary
Only a few claims are supported by the provided label excerpts (notably diabetes indication, GLP-1 receptor agonist, and common adverse reactions). Many mechanistic weight-loss/appetite/fat-burning/insulin-sensitivity/inflammation/chronic-disease claims and duration-of-use statements are not supported by the provided label text, and some safety counseling wording is potentially overbroad relative to label-specific thyroid C-cell tumor/MTC/MEN2 language.
Category Scores
Accurate Statements
Ozempic (semaglutide) is a medication used to treat type 2 diabetes.
Supported by Section 1 (INDICATIONS AND USAGE): adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Ozempic is a glucagon-like peptide-1 (GLP-1) receptor agonist.
Supported by Section 11 (DESCRIPTION) and Section 12.1 (Mechanism of Action): semaglutide is a GLP-1 receptor agonist/GLP-1 analogue and activates GLP-1 receptor.
Common side effects of Ozempic include nausea, vomiting, and diarrhea.
Supported by Section 6.1 (Clinical Trials Experience), Table 1 listing nausea, vomiting, and diarrhea as common adverse reactions.
Unsupported Statements
Ozempic mimics the action of a natural hormone that helps regulate blood sugar levels.
Partially supported: label says GLP-1 is a physiological hormone and semaglutide is a GLP-1 analogue that activates the GLP-1 receptor, but does not explicitly state it 'mimics the action' of the hormone.
Ozempic promotes weight loss by reducing food intake.
No provided label support for reducing food intake as the weight-loss mechanism.
Ozempic decreases hunger.
No provided label support for decreased hunger.
Ozempic increases feelings of fullness.
No provided label support for increased fullness.
Ozempic reduces the desire to eat by activating the brain's appetite centers.
No provided label support for brain appetite centers.
Ozempic increases fat burning by stimulating the body's natural fat-burning mechanisms.
No provided label support for fat-burning mechanisms.
Ozempic increases fat burning by activating AMP-activated protein kinase (AMPK).
No provided label support for AMPK.
Ozempic improves insulin sensitivity.
Provided label excerpts describe insulin secretion and glucagon secretion, but do not state improved insulin sensitivity.
By increasing insulin sensitivity, Ozempic helps the body better utilize insulin.
Not supported by provided label excerpts.
Ozempic reduces the risk of developing insulin resistance and related metabolic disorders by increasing insulin sensitivity.
Not supported by provided label excerpts.
Ozempic reduces inflammation in the body.
No provided label support for anti-inflammatory effects.
Ozempic's reducing inflammation can help improve insulin sensitivity.
Not supported by provided label excerpts.
Ozempic's reducing inflammation can reduce the risk of chronic diseases.
Not supported by provided label excerpts.
Ozempic is described as having a distinct mechanism for weight loss compared with other GLP-1 receptor agonists.
No provided label support for mechanism comparison vs other GLP-1 receptor agonists.
Ozempic's weight loss mechanism is described as being due to activation of the brain's appetite centers.
No provided label support for brain appetite-center activation as the mechanism.
Ozempic's weight loss mechanism is described as involving activation of the brain's reward system that regulates food intake and motivation.
No provided label support for brain reward-system activation.
People with a history of pancreatitis should consult with their doctor before taking Ozempic.
Provided label excerpt 5.2 addresses acute pancreatitis observation/discontinuation if suspected, but the specific counseling statement for 'history of pancreatitis' is not shown in the provided excerpts.
People with a history of thyroid cancer should consult with their doctor before taking Ozempic.
Provided label excerpt focuses on thyroid C-cell tumors, contraindication in patients with personal/family history of MTC or MEN2, but does not present a general 'history of thyroid cancer' consult statement.
Ozempic is approved for long-term use.
No provided label excerpts explicitly state 'approved for long-term use' or provide an indefinite/long-term approval statement.
Ozempic can be taken indefinitely if prescribed by a doctor and used as directed.
No provided label excerpts support indefinite duration of therapy.
Contradictions
Important Omissions
Ozempic indicated for cardiovascular risk reduction and chronic kidney disease risk reduction are not mentioned in the extracted claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several mechanistic and counseling/duration-of-therapy claims are not supported by the provided label excerpts, and the thyroid-related counseling is overbroad relative to the label’s specific thyroid C-cell tumor/MTC/MEN2 framing. While not an explicit contradiction, these mismatches could mislead on who should seek consult and how long therapy is intended.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Not Aligned
Primary Issue
Many extracted claims are unsupported by the provided label excerpts, especially weight-loss mechanism (hunger/appetite/reward/fat burning/AMPK), insulin sensitivity/inflammation/chronic disease risk reduction, and duration-of-use ('long-term'/'indefinitely'). Some thyroid counseling is not aligned with the label’s specific MTC/MEN2 contraindication language.
Suggested Improvement
Restrict claims to label-supported content: mechanism only as GLP-1 receptor agonism and glucose lowering described (insulin secretion/glucagon secretion; minor delay in gastric emptying). For thyroid-related safety language, use the label’s specific contraindication wording (personal/family history of MTC or MEN2) rather than 'history of thyroid cancer' consult. Remove or qualify unsupported weight-loss mechanism and duration-of-use statements unless supported by additional label sections not provided.